IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin

被引:2
作者
Osinusi, Anu [1 ,2 ]
Chary, Aarthi [3 ,4 ]
Winters, Mark A. [3 ,4 ]
Naggie, Susanna [5 ]
Masur, Henry [6 ]
Polis, Michael A. [2 ]
Kottilil, Shyam [2 ]
Holodniy, Mark [3 ,4 ]
机构
[1] NCI, CMRP, SAIC Frederick Inc, Frederick, MD 21701 USA
[2] NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA
[3] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA
[4] Stanford Univ, Stanford, CA 94305 USA
[5] Duke Clin Res Inst, Durham, NC USA
[6] NIH, Dept Crit Care Med, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
HIV; HCV; IL28B; HCV protease diversity; genomics; HUMAN-IMMUNODEFICIENCY-VIRUS; QUASI-SPECIES DIVERSITY; CHRONIC HEPATITIS-C; THERAPY; PEGINTERFERON; BOCEPREVIR; TELAPREVIR; COINFECTION; GENOTYPE-1; RESPONSES;
D O I
10.1002/jmv.23376
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Recent studies have demonstrated that IL28B polymorphisms predict therapeutic responses in chronic hepatitis C virus (HCV)-treated patients; however, the effect on HCV viral diversity, particularly on the HCV protease gene, is not clear. This study sought to evaluate the effect of IL28B polymorphisms on HCV diversity at NS3/4 protease region, which may influence therapeutic response to an HCV protease inhibitor based regimen. Twenty-two patients co-infected with HIV and HCV genotype 1, treatment-naive on stable HIV antiretroviral therapy initiating interferon-based treatment were evaluated. Plasma HCV NS3 gene diversity was analyzed by clonal analysis at baseline and end of treatment. IL28B (rs12979860) genotypes were tested for associations with virologic outcomes and diversity parameters. There was similar baseline NS3 diversity in patients with CC (favorable) genotype compared to those with CT/TT (unfavorable) genotypes. There was no significant association between IL28B genotype and baseline NS3 nucleotide p-distance, dS-dN, amino acid p-distance, or nucleotide changes. Among patients without a sustained virologic response, between baseline and follow-up there was a significant trend towards decreased diversity after treatment among patients with favorable genotype, which was not observed in unfavorable genotypes. In patients treated with peginterferon/ribavirin therapy, IL28B polymorphism was not associated with enhanced NS3 diversity at baseline. Among non-SVR patients with the less favorable genotype, there was no change in diversity after treatment. This suggests that IL28B genotype is unlikely to have a negative impact on subsequent HCV PI efficacy in patients co-infected with HIV and HCV patients who have previously failed HCV therapy. J. Med. Virol. 84:15221527, 2012. (c) Published 2012. This article is a U.S. Government work and is in the public domain in the USA.
引用
收藏
页码:1522 / 1527
页数:6
相关论文
共 33 条
  • [1] HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin
    Abbate, I
    Lo Iacono, O
    Di Stefano, R
    Cappiello, G
    Girardi, E
    Longo, R
    Ferraro, D
    Antonucci, G
    Di Marco, V
    Solmone, M
    Craxì, A
    Ippolito, G
    Capobianchi, MR
    [J]. JOURNAL OF HEPATOLOGY, 2004, 40 (05) : 831 - 836
  • [2] [Anonymous], 46 ANN M EUR ASS STU
  • [3] HIV, hepatitis C and HIV/hepatitis C virus co-infection in vulnerable populations
    Backus, LI
    Boothroyd, D
    Deyton, LR
    [J]. AIDS, 2005, 19 : S13 - S19
  • [4] Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
    Bacon, Bruce R.
    Gordon, Stuart C.
    Lawitz, Eric
    Marcellin, Patrick
    Vierling, John M.
    Zeuzem, Stefan
    Poordad, Fred
    Goodman, Zachary D.
    Sings, Heather L.
    Poordad, Fred
    Goodman, Zachary D.
    Sings, Heather L.
    Boparai, Navdeep
    Burroughs, Margaret
    Brass, Clifford A.
    Albrecht, Janice K.
    Esteban, Rafael
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (13) : 1207 - 1217
  • [5] Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection
    Bica, I
    McGovern, B
    Dhar, R
    Stone, D
    McGowan, K
    Scheib, R
    Snydman, DR
    [J]. CLINICAL INFECTIOUS DISEASES, 2001, 32 (03) : 492 - 497
  • [6] Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients
    Burney, Tabinda
    Dusheiko, Geoffrey
    [J]. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2011, 9 (02) : 151 - 160
  • [7] Recent Advances in Hepatitis C Virus Treatment: Review of HCV Protease Inhibitor Clinical Trials
    Chary, Aarthi
    Holodniy, Mark
    [J]. REVIEWS ON RECENT CLINICAL TRIALS, 2010, 5 (03) : 158 - 173
  • [8] Impact of Interferon-Ribavirin Treatment on Hepatitis C Virus (HCV) Protease Quasispecies Diversity in HIV- and HCV-Coinfected Patients
    Chary, Aarthi
    Winters, Mark A.
    Kottilil, Shyam
    Murphy, Alison A.
    Polis, Michael A.
    Holodniy, Mark
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2010, 202 (06) : 889 - 893
  • [9] Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN α-2b using TaqMan mismatch amplification mutation assay
    Curry, Stephanie
    Qiu, Ping
    Tong, Xiao
    [J]. JOURNAL OF VIROLOGICAL METHODS, 2008, 153 (02) : 156 - 162
  • [10] Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection
    Gaudieri, Silvana
    Rauch, Andri
    Park, Lawrence P.
    Freitas, Elizabeth
    Herrmann, Susan
    Jeffrey, Gary
    Cheng, Wendy
    Pfafferott, Katja
    Naidoo, Kiloshni
    Chapman, Russell
    Battegay, Manuel
    Weber, Rainer
    Telenti, Amalio
    Furrer, Hansjakob
    James, Ian
    Lucas, Michaela
    Mallal, Simon A.
    [J]. JOURNAL OF VIROLOGY, 2006, 80 (22) : 11094 - 11104